Diagnosis and treatment progress of Waldenstr?m macroglobulinemia / 白血病·淋巴瘤

ABSTRACT

The 25th Congress of the European Hematological Society (EHA) was held in the form of a virtual edition from June 11 to 21, 2020, which focused on the significance of the detection of MYD88 and CXCR4 mutations in Waldenstr?m macroglobulinemia (WM) patients by using circulating free DNA (cfDNA), as well as the clinical results of Bruton tyrosine kinase inhibitors and treatment regimen including rituximab in the front-line and relapsed WM patients.